Saamya Biotech (India) Peer Comparison

BSE: 532905

₹1.97

₹-0.10 (-4.83%)

As on 13-Aug-2018IST

Market cap

₹5 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

--

P/B Ratio

0.2

Div. Yield

0 %

Edit

	Saamya Biotech (India)	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	5	30,553	30,043	28,151	26,706
Revenue (₹ Cr)	--	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-0.02	414.00	288.22	-371.81	387.35
Net Margin (%)	--	11.23	14.79	-3.93	26.01
RoE (%)	--	8.38	29.77	-3.85	25.18
Price to Earnings	--	74.70	104.24	--	69.15
Price-To-Book	0.17	6.07	22.38	3.52	15.45

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Saamya Biotech (India)	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	14.40	4,453.22	39.17	--	153.70
Total Income	14.51	4,519.32	39.64	--	156.57
Total Expenditure	14.53	3,958.98	29.32	--	135.51
EBITDA	-0.13	494.24	9.85	--	18.19
Depreciation	0.92	141.91	4.71	--	0.80
EBIT	-1.05	352.33	5.13	--	17.39
Interest	0.00	128.96	2.64	--	2.56
Other Income	0.11	66.10	0.47	--	2.87
Exceptional Items	--	--	--	--	--
Profit before Tax	-0.94	289.47	2.96	--	17.70
Provision for Tax	-0.50	37.88	2.05	--	5.04
Profit after Tax	-0.44	251.59	0.92	--	12.66

Liabilities (₹ Cr)

	Saamya Biotech (India)	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	28.26	3,775.12	48.41	--	27.42
Minority Interest	--	465.33	--	--	--
Non-Current Liabilities	2.72	1,893.49	12.24	--	15.21
Current Liabilities	47.83	1,841.85	31.04	--	48.60
Total Liabilities	79.33	8,073.64	91.69	--	92.39

Assets (₹ Cr)

	Saamya Biotech (India)	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	27.95	4,023.94	56.39	--	24.90
Current Assets	50.85	3,951.85	35.29	--	66.17
Total Assets	79.33	8,073.64	91.69	--	92.39
Total Debt*	3.24	2,676.60	28.89	--	29.75
Net Current Assets	3.02	2,110.00	4.26	--	17.57
Contingent Liabilities	0.20	273.87	--	--	--

Cashflow (₹ Cr)

	Saamya Biotech (India)	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	0.08	71.61	7.61	--	9.86
Cash Flow from Investing Activities	0.31	-818.19	-7.87	--	-14.23
Cash from Financing Activities	-0.39	254.26	-0.26	--	4.37
Net Cash Inflow / Outflow	0.00	-492.32	-0.51	--	-0.01

Ratios

Profitability Ratios

	Saamya Biotech (India)	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	-2.93	6.87	7.44	--	35.54
ROE (%)	-1.55	7.07	3.16	--	46.43
ROA (%)	-0.58	3.25	1.04	--	13.87
EBIT Margin (%)	-0.12	12.58	26.35	--	13.70
Net Margin (%)	-3.04	5.57	2.31	--	8.08
Cash Profit Margin (%)	3.15	8.84	14.36	--	8.75

Growth Ratios

	Saamya Biotech (India)	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	-49.94	-0.63	-0.11	--	0.00
EBIT Growth (%)	-106.73	-27.79	-10.14	--	24.42
Net Profit Growth (%)	35.01	-39.04	-65.67	--	0.00
EPS Growth (%)	35.01	-38.31	-65.67	--	0.00
Book Value Growth (%)	-1.53	11.15	3.21	--	0.00

Valuation Ratios

	Saamya Biotech (India)	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	0.00	39.52	0.00	--	0.00
Price / Book Value	0.37	2.87	0.00	--	0.00
Dividend Yield (%)	0.00	0.00	--	--	--
EV/EBITDA	-773.68	21.33	4.77	--	1.46
Market Cap (₹ Cr)	10.53	10,753.31	0.00	--	0.00

Solvency Ratios

	Saamya Biotech (India)	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.11	0.71	0.60	--	1.09
Short term debt to equity ratio	--	0.15	0.31	--	0.42
Current Ratio	1.06	2.15	1.14	--	1.36
Quick Ratio	1.06	1.55	1.07	--	0.96
Interest Coverage	-399.67	3.24	2.12	--	7.92

Operating Efficiency Ratios

	Saamya Biotech (India)	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	348.41	24.96	48.35	--	23.62
Asset Turnover	0.20	0.58	0.45	--	1.68
Receivable days	1,126.58	75.93	166.45	--	86.20
Inventory Days	0.00	87.00	13.89	--	46.64
Payable days	1,100.53	134.61	247.85	--	113.37
Cash Conversion Cycle	26.06	28.32	-67.51	--	19.47

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly